Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Afsaneh Barzi

Afsaneh Barzi

MD, PhD
City of Hope Comprehensive Cancer Center, Duarte, CA

Academic History:

Afsaneh Barzi, MD, PhD, is a medical oncologist specializing in the treatment of gastrointestinal cancers at City of Hope Comprehensive Cancer Center, in Duarte, CA.

Dr Barzi earned her medical degree at Tehran University of Medical Science, in Tehran, Iran before completing a residency in internal medicine and earning a PhD in public health at the University of Texas, in Austin, TX. Following this, she completed a fellowship in hematology and oncology at the Cleveland Clinic Taussig Cancer Center, in Cleveland, OH.

She is a member of the Alliance Cancer Care Delivery Committee, the SWOG Gastrointestinal Committee and Cancer Care Delivery Committee, as well as the American Society of Medical Oncology (ASCO). Her work has been recognised with various accolades, including the Young Investigator Award from the Southwestern Oncology Group in 2011 and the Travel Award for Markers in Cancer in 2013.

Speaking on novel therapeutics for the treatment of gastrointestinal cancers

Dr Barzi’s research focuses on the development of new cancer therapies for the treatment of gastrointestinal cancers affecting the colon, rectum, pancreas, stomach and liver. She has been involved in several clinical trials, notably the recent Phase II trial investigating the safety and efficacy of neoadjuvant bevacizumab with modified FOLFOX7 for the treatment of patients with stage II and III rectal cancer (NCT01871571). In addition, her research interests include healthcare economics and the metrics of healthcare quality for improving patient care.

Clinical applications of liquid biopsies in colorectal cancer 1:14
Clinical applications of liquid biopsies in colorectal cancer
Afsaneh Barzi • 21 Jan 2023
The current state of MRD testing in colorectal cancer 2:27
The current state of MRD testing in colorectal cancer
Afsaneh Barzi • 21 Jan 2023
Assessing the rate of ER utilization prior to CRC diagnosis 2:57
Assessing the rate of ER utilization prior to CRC diagnosis
Afsaneh Barzi • 21 Jan 2023
How can we mitigate health inequalities in colorectal cancer? 1:18
How can we mitigate health inequalities in colorectal cancer?
Afsaneh Barzi • 21 Jan 2023
The rationale for combining regorafenib with IO to treat patients with refractory MSS-CRC 1:23
The rationale for combining regorafenib with IO to treat patients with refractory MSS-CRC
Afsaneh Barzi • 17 Jan 2022
Prior RT may potentially enhance treatment of MSS-CRC with regorafenib and pembrolizumab 6:56
Prior RT may potentially enhance treatment of MSS-CRC with regorafenib and pembrolizumab
Afsaneh Barzi • 17 Jan 2022
Key updates at ASCO GI 2022 0:56
Key updates at ASCO GI 2022
Afsaneh Barzi • 17 Jan 2022
Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer 4:03
Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer
Afsaneh Barzi • 18 Jan 2021
MOUNTAINEER-02: tucatinib in previously treated HER2+ gastric cancer 2:23
MOUNTAINEER-02: tucatinib in previously treated HER2+ gastric cancer
Afsaneh Barzi • 15 Jan 2021
Disparities in access to screening and variation of targets in different groups 1:31
Disparities in access to screening and variation of targets in different groups
Afsaneh Barzi • 18 Jan 2021
Health-related quality of life in young CRC survivors 3:15
Health-related quality of life in young CRC survivors
Afsaneh Barzi • 18 Jan 2021
The content of VJOncology is intended for healthcare professionals